- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Advancing Care in AML: Exploring Novel Treatment Options
Panelists discuss how acute myeloid leukemia treatment has evolved from a one-size-fits-all approach to personalized medicine incorporating genetic profiling, targeted therapies like venetoclax and IDH inhibitors, emerging oral regimens, and comprehensive patient assessments that consider not only traditional fitness criteria but also social determinants of health, quality of life factors, and the potential for curative versus palliative care in different patient populations.
EP. 1: Overview of Pathophysiology of and Progression of AML
Panelists discuss how the pathophysiology of acute myeloid leukemia has evolved from a single phenotype understanding to recognizing diverse genetic events that lead to transformation at the hematopoietic stem cell level, with treatment decisions now increasingly integrated with specific genetic mutations despite the disease’s rapid progression timeline.
Watch
EP. 2: Risk Classification Systems in AML
Panelists discuss how current risk stratification systems, particularly the European Leukemia Net 2022 classification for intensive therapy and the 2024 classification for lower intensity treatments, categorize patients based on complex cytogenetics and molecular features to guide prognosis and treatment selection.
Watch
